BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Genetown

  BioNTech-Pfizer Increase COVID-19 Vaccine Output Target Again

  With the ongoing global pandemic, BioNTech and Pfizer announced that they will be boosting their manufacturing capacity of the COVID-19 vaccine to 2.5 billion for 2021.

  March 30, 2021

   · 

  2 min read

   · 

  Kristiane Polido
• 

  Business

  TCR2 Therapeutics Leases Manufacturing Space in Maryland, Autolus Backs Out of U.S. Expansion

  After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.

  March 30, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Takeda Pairs Up With BridGene to Solve “Undruggable” Neurodegenerative Diseases

  The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.

  March 30, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Merck’s Busy Day: FDA Rejection, EU Recommendation and a Spinoff Sale

  Merck is having a very busy week. Here’s today’s news.

  March 30, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  After About 50 Years, the mRNA Revolution is Here

  Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.

  March 30, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Global Vaccine Passports Edge Closer, Speeding Arrival of the Next “Normal”

  Vaccine passports are an interim step that can speed the return of some semblance of normality by allowing the rapidly growing numbers of vaccinated people to travel more easily and to attend typically crowded sporting events, concerts and religious services.

  March 30, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Genetown

  Omega Raises $126 Million to Unlock Potential of Epigenomic Controller Candidate

  Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.

  March 30, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck KGaA’s ATR Inhibitor Shows Promise in Both Cancer and COVID-19

  A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.

  March 30, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Money on the Move: March 24-30

  Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.

  March 30, 2021

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Deals

  Antitrust Concerns Hinder Second Illumina Acquisition, FTC Raises Concern Over $8 Billion Deal for Grail

  Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.

  March 30, 2021

   · 

  3 min read

   · 

  Alex Keown